Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions

Ligand Pharmaceuticals Incorporated LGND announced today that a poster entitled “LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes” was presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA), June 8-12, 2012, in Philadelphia. The poster provides data from preclinical studies of a novel compound, LGD-6972 that has demonstrated promising glucose lowering activity in various animal models of type 2 diabetes. In preclinical studies, Ligand evaluated the efficacy, pharmacokinetics, and safety of LGD-6972.